Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

For healthcare investors seeking long-term growth, the choice between Johnson & Johnson (NYSE:JNJ) and Thermo Fisher (NYSE:TMO) is not a simple one. Both companies demonstrate strong fundamentals, but their growth trajectories differ significantly. Johnson & Johnson (NYSE:JNJ) benefits from a well-rounded portfolio, with pharmaceuticals, medical technology, and a robust pipeline driving revenue.

Despite a 55% drop in Stelara sales due to a patent loss, their Tremfya drug and other immunology products have more than made up for the decline. Thermo Fisher (NYSE:TMO), on the other hand, relies heavily on life sciences industry growth and has seen a rebound in its Analytical Instruments segment. While its Life Sciences Solutions and bioproduction businesses have shown positive signs, organic revenue remains below its historic double-digit growth rates.

Both companies face risks: Johnson & Johnson (NYSE:JNJ) may struggle with a slow return to its MedTech growth, while Thermo Fisher (NYSE:TMO) must prove that the current life sciences spending recovery is sustainable. Ultimately, Johnson & Johnson (NYSE:JNJ) offers greater resilience in case industry conditions worsen, but Thermo Fisher (NYSE:TMO) could provide cyclical upside if the life sciences sector continues to improve.